Twitter Linkedin Envelope
REQUEST A CALL

Announcing the Launch of The Association of Diversity in Clinical Trials

Press Releases

/

February 3, 2023

DALLAS, Feb. 3, 2023 /PRNewswire/ — The Association of Diversity in Clinical Trials (AOD) is being launched and introduced at upcoming industry conferences SCOPE and the Health Equity in Clinical Trials Congress this month. The AOD will become the first entity to represent industry in an effort to meet new government and regulatory demands in the field of diversity.

The mission of the organization is to bring industry leaders together to establish much needed standards and best practices related to improving the representation of diverse participants in clinical trials. This will be achieved through the development, integration, and monitoring of quality and consistent diversity methodology across the research industry. 

Dr. Jerome Adams, Chairman of the Board of the AOD and former US Surgeon General stated, “there is no time like the present to take action on behalf of industry to develop standards, GCPs, and practices to guide and establish direction in this rapidly growing area of importance.  Being involved in this groundbreaking step forward, is critical to the path towards progress for participants of diverse backgrounds.”

Dr. Diana Foster, who will share her significant experience in leading many initiatives in diversity believes, “the changing face of clinical trials will require a collaborative vision for change to be executed across the clinical trial spectrum. This will require consensus at a high level and the development of actionable standards to move the needle.”

A prestigious Advisory Board of leaders will be announced soon who will support this unprecedented step towards the assurance of representative diversity and inclusion in clinical trials.

Diana Foster, Ph.D.
The Association of Diversity in Clinical Trials
[email protected]

SOURCE The Association of Diversity in Clinical Trials

REQUEST A CALL

Diana L. Foster, Ph.D

CEO and Chief Diversity Officer for TOTAL Diversity Clinical Trial Management

Diana L. Foster, Ph.D., is the CEO and Chief Diversity Officer for TOTAL Diversity Clinical Trial Management, a full-service Diversity Organization whose mission is to enhance diversity and inclusion in clinical research trials. Foster has served as the Vice President of Diversity, Equity, and Inclusion for the Society of Clinical Research Sites (SCRS) since 2016. She also held a position as the Vice President of Strategy and Development for SCRS originating programs such as the Global Impact Partner Programs and many other industry supported initiatives.

Foster is a thought-leader and sought-after expert in diversity and clinical site best practices. She is the author of the Diversity Site Assessment Tool and has published numerous research papers on the topic. Over the past two decades, she has addressed audiences across the world, published multiple papers and articles, and written five authoritative industry books including Global Issues in Patient Recruitment and Retention.

Jerome Adams, M.D.

Chairman of the Board for TOTAL Diversity Clinical Trial Management

Dr. Adams also currently serves as Executive Director of Health Equity Initiatives at Purdue University. He formerly served as the 20th United States Surgeon General and as a member of the President’s COVID-19 task force, where he was at the forefront of America’s most pressing health challenges throughout the pandemic, including working with companies to increase diversity in vaccine trials.

As the Chairman of the Board for TOTAL Diversity, Dr. Adams provides his in-depth knowledge of patient perspectives and industry views on diversity to create sustainable solutions and best practices to establish more diverse representation in clinical trials.